Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials

被引:13
作者
An, Mao Mao [1 ]
Zou, Zui [2 ]
Shen, Hui [3 ,4 ]
Gao, Ping Hui [1 ]
Cao, Yong Bing [1 ]
Jiang, Yuan Ying [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, R&D Ctr New Drugs, Shanghai 200433, Peoples R China
[2] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Beijing 100037, Peoples R China
[4] Cardiovasc Inst, Beijing 100037, Peoples R China
关键词
Moxifloxacin; beta-Lactams; Community-acquired pneumonia; Meta-analysis; IN-VITRO ACTIVITY; ORAL MOXIFLOXACIN; BAY; 12-8039; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL THERAPY; HOSPITALIZED-PATIENTS; SEQUENTIAL IV; FLUOROQUINOLONES; QUALITY; 8-METHOXYQUINOLONE;
D O I
10.1016/j.ijantimicag.2010.03.010
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic, with beta-lactam-based standard therapy, which has been reported to possess good efficacy for community-acquired pneumonia (CAP). A meta-analysis of randomised controlled trials (RCTs) identified in PubMed, the Cochrane Library and Embase was performed. Seven RCTs, involving 3903 patients, were included in the meta-analysis. Moxifloxacin monotherapy was associated with similar clinical treatment success rates [ clinically evaluable population, odds ratio (OR) = 1.15, 95% confidence interval (CI) 0.81-1.64; intention-to-treat population, OR=1.11, 95% CI 0.86-1.42] and similar mortality (OR = 0.98, 95% CI 0.66-1.46) compared with beta-lactam-based standard therapy for CAP. Microbiological treatment success rates in the moxifloxacin group were significantly higher than in the beta-lactam-based therapy group with a statistical margin (OR = 1.69, 95% CI 1.02-2.80). No difference was found regarding the incidence of adverse events and serious adverse events between moxifloxacin and beta-lactam-based standard therapy. This meta-analysis provides evidence that moxifloxacin not only can be used as effectively and safely as beta-lactam-based standard therapy for CAP but also possesses a favourable pathogen eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for beta-lactam-based standard therapy. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:58 / 65
页数:8
相关论文
共 40 条
[1]  
[Anonymous], 2000, METHODS METAANALYSIS
[2]   Resistance among Streptococcus pneumoniae:: Implications for drug selection [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1613-1620
[3]   In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas [J].
Bébéar, CM ;
Renaudin, H ;
Boudjadja, A ;
Bébéar, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :703-704
[4]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[5]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[6]   Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance [J].
Boswell, FJ ;
Andrews, JM ;
Jevons, G ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :495-502
[7]   In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against and Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].
Brueggemann, AB ;
Kugler, KC ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1594-1597
[8]   Penicillin-resistant Streptococcus pneumoniae:: Review of moxifloxacin activity [J].
Dalhoff, A ;
Krasemann, C ;
Wegener, S ;
Tillotson, G .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S22-S29
[9]   Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia [J].
Davis, SL ;
Delgado, G ;
McKinnon, PS .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S136-S143
[10]   Mutant selection window hypothesis updated [J].
Drlica, Karl ;
Zhao, Xilin .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (05) :681-688